Press Release: Novartis presents new long-term -2-

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 103,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. RS Wright, FJ Raal, W Koenig, U Landmesser, LA Leiter, GG Schwartz, A

Lesogor, P Maheux, Z Talloczy, S Vikarunnessa, X Zang, KK Ray. ORION-8:

Long-term efficacy and safety of twice-yearly inclisiran in high

cardiovascular risk patients. Data presented at the ESC Congress on

August 28, 2023.

2. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in

Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507--

1519.

3. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of

Heterozygous Familial Hypercholesterolemia. N Engl J Med.

2020;382(16):1520-- 1530.

4. Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional

Observational Study of Lipid-Modifying Therapy Use in Secondary and

Primary Care: the DA VINCI study. Eur J Prev Cardiol.

2021;28(11):1279-1289.

5. ClinicalTrials.Gov. ORION-8 (NCT03814187). Accessed July 14, 2023.

https://www.clinicaltrials.gov/study/NCT03814187

6. Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety

of inclisiran in patients with high cardiovascular risk and elevated LDL

cholesterol (ORION-3): results from the 4-year open-label extension of

the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109-119.

7. Novartis. Data on file.

8. Food and Drug Administration (FDA). Leqvio. Last updated July 2023.

Accessed July 14,

2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214012s00

9lbl.pdf

9. European Medicines Agency (EMA). Leqvio. Last updated December 2020.

Accessed July 14, 2023.

https://www.ema.europa.eu/en/documents/overview/leqvio-epar-medicine-overview_en.pdf

10. National Medical Products Administration (NMPA). August 23 Drug Approval

Information. Accessed August 25, 2023.

https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230824155809182.html

11. Novartis. Media release. US FDA approves expanded indication for Novartis

Leqvio(R) (inclisiran) to include treatment of adults with high LDL-C and

who are at increased risk of heart disease. July 10, 2023.

https://www.novartis.com/us-en/news/media-releases/us-fda-approves-expanded-indication-novartis-leqvio-inclisiran-include-treatment-adults-high-ldl-c-and-who-are-increased-risk-heart-disease

12. Lansberg P, Lee A, Lee ZV, Subramaniam K, Setia S. Nonadherence to

statins: individualized intervention strategies outside the pill box.

Vasc Health Risk Manag. 2018;14:91-102.

13. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High

Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med.

2017;376(15):1430-1440.

14. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from

plaques to genes to statins. Cell. 2015;161(1):161-172.

15. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on

Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol.

2018;72(10):1141-1156.

16. World Health Organization (WHO). Cardiovascular diseases (CVDs).

Published June 2021. Accessed October

2022. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-dis

eases-(cvds)

17. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke

Statistics--2012 update: A report from the American Heart Association.

Circulation. 2012;125(1):e2-e220.

18. Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic

cardiovascular disease and its risk factors in Korea: a nationwide

population-based study. BMC Public Health. 2019;19(1):1112.

19. National Cholesterol Education Program (NCEP) Expert Panel on Detection,

Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult

Treatment Panel III). Third Report of the National Cholesterol Education

Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of

High Blood Cholesterol in Adults (Adult Treatment Panel III) final

report. Circulation. 2002;106(25):3143-3421.

20. World Health Organization (WHO). Fact sheet. Non-communicable diseases.

Published June 2018. Accessed October 2022.

https://www.who.int/news-room/fact-sheets/detail/noncommunicable-disease

s

21. World Health Organization (WHO). Cardiovascular diseases: Avoiding heart

attacks and strokes. Published September 2015. Accessed October 2022.

https://www.who.int/news-room/questions-and-answers/item/cardiovascular-diseases-avoiding-heart-attacks-and-strokes

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267 Marlena Abdinoor +1 617 335 9525

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

August 28, 2023 08:15 ET (12:15 GMT)